- Home
- Companies
- san marino
- t and b cell
Show results for
Refine by
T And B Cell Suppliers Serving San Marino
48 companies found
based inChuo-ku, JAPAN
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are ...
Adaptate Biotherapeutics is focussed on therapeutic antibodies which harness the potential of patients’ own gamma delta T cells in situ. Gamma delta T cells play a critical role in immune surveillance, recognising malignant/transformed ...
based inBoston, MASSACHUSETTS (USA)
At PathAI, we’re dedicated to improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma, laboratories, and clinicians — aiming to provide patients with access to accurate diagnoses and effective ...
based inPlanegg, GERMANY
TQ Therapeutics GmbH is pioneering a novel approach to cell and gene therapy with its TQx platform, which transforms the production of cellular therapies into a rapid, automated process that occurs at the patient's side. This method leverages ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
ZYF0033 is effective in inhibiting hematopoietic progenitor cells HPK1, basically inhibiting MBP protein oxidation IC50 10 nM . ZYF0033 promotes anti-cancer immune response, lowers SLP76 (acid 376) oxidation. ZYF0033 Suppression 4T-1 Small mouse ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Patients eligible for clinical trials with ACTengine® product candidates have a portion of their white blood cells collected using a well-established process called leukapheresis, a procedure in which a fraction of the white blood cells of a ...
based inCambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...
We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody ...
based in, NEW JERSEY (USA)
Founded in 2013 by a group of passionate synthetic biologists with decades of industry experience and a proven track record of delivering cost-effective DNA solutions, Synbio Technologies is incorporated with a single mission in mind: to empower ...
Immune Repertoire refers to the set of all functionally diversified B cells and T cells in the circulatory system of an individual at any given time. Immune repertoire sequencing ...
based inState College, PENNSYLVANIA (USA)
SoftGenetics, LLC specializes in the development of genetic analysis tools for both research and diagnostic ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our ADP-A2M4CD8 SPEAR T-cell therapy is our first "next-generation" therapy and is directed to MAGE-A4, a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. What differentiates this therapy from our ...
based inCounty of New Castle, DELAWARE (USA)
MedGenome Inc. is a global leader in personalized medicine with unique genomic solutions in immuno-oncology, diabetes, ophthalmology, cardiology and other rare diseases. Founded in 2013, MedGenome currently has a Next Generation Sequencing (NGS) ...
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic ...
based inSeattle, WASHINGTON (USA)
AVM Biotechnology is developing and advancing AVM0703, a proprietary formulation of concentrated dexamethasone. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
Chimeric Antigen Receptor T cells (CAR-T) are genetically engineered T cells that are modified to express an artificial T cell receptor on their surface that binds and targets cancer proteins in an HLA-independent ...
based inHolytown, UNITED KINGDOM
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to ...
Our therapies are focused on leveraging the inherent biological capabilities of gamma delta T cells (GDT cells) together with an integrated cell engineering approach. GDT cells are a component of the lymphocytes (white blood cells) present within ...
based inSan Francisco, CALIFORNIA (USA)
MiLaboratories is the leader in immunome data analysis software with flagship product MiXCR. We provide a secure, scalable, and fast solution that helps thousands of researchers around the globe to discover new drugs and therapies. We develop ...
MiXCR Platform is an integrated solution for fast and rigorous interactive analysis of T-cell and B-cell receptor repertoire high-throughput sequencing ...
based inSan Francisco, CALIFORNIA (USA)
We were founded with the mission of creating a world without infectious disease. We are a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. ...
We are exploiting the unique immunology of human cytomegalovirus, or HCMV, a commonly occurring virus in humans, as a delivery vehicle – or vector – for vaccines to potentially treat and prevent infection by pathogens that are refractory ...
based inAlameda, CALIFORNIA (USA)
Since its inception in 1998, AllCells, a Discovery Life Sciences Company, has focused on advancing science in an innovative, collaborative, and client-centric manner. In our corporate video, AllCells’ Founder, Jay Tong, describes his early days in ...
Leukopaks are enriched leukapheresis products collected from healthy and consenting donors using the Spectra Optia® Apheresis System following an IRB-approved protocol. Leukopaks typically contain up to 50% T ...
based inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
based inDuisburg, GERMANY
Genekam Biotechnology AG was found in 1999. It started offering DNA-Tests in 2001. From 2004, it started development of PCR kits while exporting to 5 countries, today (2015) it exports to 70 countries in the world. Genekam covers different targets ...
There are many laboratories developing CAR T-cell therapies. Genekam has a number of kits to develop CAR T-Cell therapy e.g. isolate large number of T cells (CD4 / CD8) from blood or other source. This isolation kit will generate larger number of ...